Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure - 25/01/24
Doi : 10.1016/S1473-3099(23)00744-2
Sijie Yang a, e, f, †, Yuanling Yu e, †, Yanli Xu g, Fanchong Jian a, b, e, Weiliang Song a, c, e, Ayijiang Yisimayi a, c, e, Peng Wang e, Jing Wang e, Jingyi Liu a, d, e, Lingling Yu e, Xiao Niu a, c, e, Jing Wang a, c, e, Yao Wang e, Fei Shao e, Ronghua Jin g, Youchun Wang e, h, Yunlong Cao a, c, e 
a Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China
b College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
c School of Life Sciences, Peking University, Beijing 100871, China
d College of Future Technology, Peking University, Beijing 100871, China
e Changping Laboratory, Beijing, China
f Peking–Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China
g Beijing Ditan Hospital, Capital Medical University, Beijing, China
h Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, China
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
© 2024
Elsevier Ltd. Tous droits réservés.
Vol 24 - N° 2
P. e70-e72 - février 2024 Retour au numéro
Article précédent
- Good news for travellers, but what do rabies vaccines say about global health?
- Katie Hampson
- Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study
- Christian Holm Hansen, Ida Rask Moustsen-Helms, Morten Rasmussen, Bolette Søborg, Henrik Ullum, Palle Valentiner-Branth
Bienvenue sur EM-consulte, la référence des professionnels de santé.